Cobra and Auxilium extend agreement to manufacture AA4500
UK-based Cobra Biomanufacturing and Auxilium Pharmaceuticals, of Malvern, Pennsylvania, have extended their agreement for the production and supply of the protein biopharmaceutical AA4500.
UK-based Cobra Biomanufacturing and Auxilium Pharmaceuticals, of Malvern, Pennsylvania, have extended their agreement for the production and supply of the protein biopharmaceutical AA4500.
Under the agreement, Cobra will provide scale-up and cGMP manufacturing services and supply of drug for Phase II/III clinical trials. AA4500 is being developed by Auxilium as a potential treatment of Peyronie's and Dupuytren's Disease and has been granted orphan drug status by the FDA.
The value of the agreement is in excess of US$3.3m for process development and clinical lot production through 2006.
'This agreement cements a strong and productive relationship with Auxilium and gives Cobra the opportunity to deploy its skills in biologics process development and production of this potentially exciting and innovative product candidate,' said David Thatcher, ceo of Cobra Biomanufacturing.